MAP2K1 and glioblastoma: Furthermore, we observed neither MEK1 mutations nor MEK1 CNVs in ACC, UCS, UVM, DLBC, acute myeloid leukemia (AML), GBM, renal papillary cell carcinoma (PRCC), LGG and PAAD (Fig. 6A).